Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- المصدر:Journal of Diabetes Research. 10/12/2024, Vol. 2024, p1-22. 22p.
No Comments.